| Term | Real-World Evidence (RWE) |
| Definition | Clinical evidence about a medical product's usage, benefits, or risks derived from analysis of real-world data (RWD) collected outside traditional clinical trials. |
| Relevant to | Medical Affairs, MSLs, HEOR teams, regulatory affairs, market access, pharmacovigilance |
| Regulatory basis | 21st Century Cures Act (2016); FDA RWE Framework (2018); EMA DARWIN EU |
| Related glossary terms | Medical Affairs · Medical Science Liaison (MSL) · Key Opinion Leader (KOL) · Medical Insights · Field Medical |
Real-world evidence (RWE) is clinical evidence about the usage and potential benefits or risks of a medical product derived from the analysis of real-world data (RWD). The FDA defines RWD as data relating to patient health status and the delivery of health care routinely collected from sources outside traditional randomized controlled trials (RCTs) including electronic health records (EHRs), medical claims and billing data, product and disease registries, patient-reported outcomes, and data from digital health technologies such as wearables.
Where RCTs measure how a drug performs under tightly controlled conditions with narrowly selected patient populations, RWE captures how treatments actually work across the full diversity of everyday clinical practice different patient demographics, comorbidities, adherence patterns, and care settings. This distinction makes RWE an essential complement to trial data, not a replacement for it.
The regulatory foundation for RWE's role in drug development was formalized by the 21st Century Cures Act, signed into law in December 2016. This legislation directed the FDA to create a framework for evaluating how RWE could support the approval of new indications for already-approved drugs and satisfy post-approval study requirements. The FDA published that framework in 2018 and has since issued a series of guidance documents addressing RWD sources, study design, data standards, and submission requirements.
In December 2025, the FDA took a significant further step by announcing that it would accept RWE in regulatory submissions without requiring sponsors to submit identifiable individual patient data in all cases opening the door to de-identified databases containing millions of patient records from cancer registries, hospital systems, insurance claims databases, and EHR networks.
The pharmaceutical industry generates enormous volumes of clinical data, yet historically has relied primarily on RCTs to support regulatory and commercial decisions. RCTs remain the gold standard for establishing efficacy, but they come with well-documented constraints: they are expensive (clinical trials account for roughly 40% of the pharma industry's R&D budget in the US), they take years to complete, they enroll narrowly defined patient populations, and their controlled conditions may not reflect how treatments perform in routine practice.
RWE addresses these gaps in several ways.
It reveals how treatments perform in broader populations. RCT participants are typically younger, healthier, and less diverse than real-world patients. RWE captures outcomes across the full spectrum of patients who actually receive a treatment including elderly patients, those with multiple comorbidities, and underrepresented demographic groups. This gives clinicians and payers a more complete picture of a product's benefit-risk profile.
It accelerates evidence generation. Generating RWE from existing data sources EHRs, claims databases, registries can be significantly faster than designing and executing a new clinical trial. Industry estimates suggest that generative AI is now compressing RWE study cycle times by 30–40%, making evidence generation faster and more scalable.
It supports the full product lifecycle. RWE informs decisions at every stage: identifying unmet medical needs during early research, supporting regulatory submissions for new indications, demonstrating comparative effectiveness for payers and health technology assessment (HTA) bodies, monitoring post-market safety through pharmacovigilance, and guiding treatment guideline development.
It is a growing market. The global RWE solutions market was valued at approximately $2.6–5.4 billion in 2025 (estimates vary by scope), with projections showing double-digit compound annual growth rates through the end of the decade reflecting how central RWE has become to pharmaceutical strategy.
The terms RWD and RWE are often used interchangeably, but they refer to different things. Understanding the distinction is important for Medical Affairs teams that communicate evidence to HCPs and internal stakeholders.
| Real-World Data (RWD) | Real-World Evidence (RWE) | |
|---|---|---|
| What it is | Raw data about patient health status and health care delivery | Clinical evidence derived from analysis of RWD |
| Sources | EHRs, medical claims, disease registries, pharmacy dispensing records, wearables, patient-reported outcomes | Studies, analyses, and conclusions generated from RWD |
| Analogy | The raw ingredients | The finished dish |
| Example | A database of 500,000 EHR records showing prescribing patterns for a cardiovascular drug | A published study analyzing those records to demonstrate that the drug reduces hospitalizations by 18% in patients over 65 |
| Regulatory relevance | Must be assessed for quality, relevance, and reliability before it can generate RWE | Used to support regulatory submissions, label expansions, and post-market commitments |
In short: RWD is data. RWE is the evidence you derive from analyzing that data with rigorous methodology. Not all RWD produces RWE the data must be fit-for-purpose, and the analysis must meet scientific and regulatory standards.
RWE and RCTs are not competitors they serve complementary roles in the evidence hierarchy. Medical Affairs professionals, especially MSLs, need to communicate this distinction clearly during scientific exchange with HCPs.
| Randomized Controlled Trials (RCTs) | Real-World Evidence (RWE) | |
|---|---|---|
| Setting | Controlled clinical environment | Routine clinical practice |
| Patients | Narrowly selected per inclusion/exclusion criteria | Broad, diverse real-world populations |
| Primary strength | Internal validity (establishes causation) | External validity (reflects real-world effectiveness) |
| Limitations | May not generalize to real-world populations; expensive; time-consuming | Susceptible to confounding and bias; data quality varies |
| Cost | $2.6 billion average per drug (full development) | Significantly lower per study when leveraging existing data sources |
| Duration | Years (often 3–7 years for pivotal trials) | Months to 1–2 years depending on study design |
| Regulatory role | Primary basis for initial drug approval | Supports new indications, post-market surveillance, label expansions |
| Use in Medical Affairs | Foundation of clinical messaging and labeling | Informs KOL discussions, treatment guideline input, payer evidence, insight generation |
The most effective Medical Affairs strategies use both. RCTs establish foundational efficacy and safety. RWE extends and deepens that evidence by showing how products perform in the populations and settings where medicine actually happens.
RWD comes from a range of sources, each with distinct strengths and limitations that Medical Affairs teams should understand:
Electronic health records (EHRs): Detailed clinical data including diagnoses, lab results, medications, procedures, and physician notes. EHRs provide rich longitudinal views of patient care but can be inconsistent in data coding and completeness across health systems.
Medical claims and billing data: Insurance claims and pharmacy dispensing records covering large patient populations. Claims data are broad and longitudinal but lack clinical detail, they show what was billed, not necessarily why.
Disease and product registries: Structured databases tracking specific conditions or treatments. Registries offer high data quality within their scope but are limited to enrolled populations.
Patient-reported outcomes (PROs): Data collected directly from patients about symptoms, quality of life, and treatment experience. PROs capture the patient perspective that clinical data often misses.
Digital health technologies: Wearables, mobile health apps, and biosensors generating continuous real-time data on physical activity, vital signs, medication adherence, and more. This is the fastest-growing RWD source, though standardization remains a challenge.
RWE has moved from a supplementary data source to a strategic pillar of Medical Affairs operations. Here is how it applies across core Medical Affairs functions:
Evidence generation and communication. Medical Affairs teams collaborate with HEOR (Health Economics and Outcomes Research) and epidemiology functions to design and execute RWE studies that fill evidence gaps left by clinical trials. MSLs then communicate these findings to HCPs during scientific exchange presenting RWE on treatment effectiveness in specific subpopulations, long-term safety profiles, and comparative outcomes that physicians need to make informed clinical decisions.
KOL engagement. RWE enables MSLs to deliver data specific to the patient populations, conditions, and clinical questions a KOL is investigating. Instead of presenting only trial data with narrow inclusion criteria, MSLs armed with RWE can discuss outcomes in real-world cohorts that mirror the KOL's patient mix building scientific credibility and deepening engagement.
Medical insight capture and strategy. When MSLs capture field insights from HCP interactions questions about real-world treatment patterns, concerns about outcomes in specific populations, feedback on unmet needs those insights often point directly to RWE gaps that the organization should address. The insight-to-evidence feedback loop is one of Medical Affairs' most strategic contributions.
Post-market safety monitoring. RWE supports ongoing pharmacovigilance by enabling the detection of adverse event signals across large, diverse patient populations that trials never captured. Medical Affairs teams work with safety and regulatory functions to interpret these signals and communicate updated safety information to HCPs.
Market access and payer engagement. Payers and HTA bodies increasingly demand evidence of real-world effectiveness and cost-effectiveness — not just trial efficacy. Medical Affairs and HEOR teams generate RWE to support reimbursement negotiations, formulary discussions, and value-based contracting.
Treatment guideline development. RWE contributes to clinical practice guidelines and treatment pathways by providing data on comparative effectiveness, treatment sequencing, and outcomes in populations underrepresented in trials. MSLs play a key role in disseminating guideline-relevant evidence to clinical decision-makers.
TikaMobile's Medical Affairs platform connects the workflows that turn field intelligence into actionable evidence — from capturing MSL insights that identify RWE gaps to tracking the engagement outcomes that demonstrate Medical Affairs' strategic impact.
TikaMobile's Insights Management captures and classifies field insights at the point of interaction, routing them to the right stakeholders with clear accountability — so observations about real-world treatment patterns, unmet needs, and evidence gaps don't die in CRM notes. TikaDiscover helps MSL teams identify and prioritize the KOLs conducting RWE-relevant research, and TikaMobile's Medical Affairs CRM tracks per-KOL engagement plans and outcomes so leaders can measure the impact of evidence-driven scientific exchange.
What is the difference between real-world evidence and clinical trial data? Clinical trial data comes from controlled studies with specific inclusion criteria, while RWE comes from analyzing data collected during routine clinical practice. Trials establish whether a treatment can work under ideal conditions (efficacy); RWE shows how it actually works in everyday care (effectiveness). Both are essential — trials for regulatory approval, RWE for understanding real-world performance.
What are the main sources of real-world data in pharma? The primary sources include electronic health records (EHRs), medical claims and billing data, disease and product registries, patient-reported outcomes, and digital health technologies such as wearables. Each source has different strengths: EHRs provide clinical depth, claims data offer population breadth, and registries deliver disease-specific detail.
How does the FDA use real-world evidence? The FDA uses RWE to support the approval of new indications for already-approved drugs, to satisfy post-approval study requirements, and to monitor post-market safety. The 21st Century Cures Act (2016) formalized this role, and the FDA has since issued multiple guidance documents on RWD quality, study design, and data standards for regulatory submissions.
Why is RWE important for Medical Affairs and MSLs? RWE gives MSLs evidence that reflects the patient populations and clinical settings their HCPs actually work in — not just trial populations. It strengthens scientific exchange, informs KOL engagement strategy, supports payer discussions, and helps Medical Affairs demonstrate strategic value through the insight-to-evidence feedback loop.
Can real-world evidence replace clinical trials? No. RWE complements clinical trials but does not replace them. RCTs remain the gold standard for establishing causal efficacy and are required for initial drug approvals. RWE's strength is in extending evidence to broader populations, longer time horizons, and real-world care settings where clinical trials cannot practically operate.
What is the difference between RWD and RWE? Real-world data (RWD) is the raw data collected from sources like EHRs, claims, and registries. Real-world evidence (RWE) is the clinical evidence derived from rigorous analysis of that data. RWD is the input; RWE is the output. Not all RWD becomes RWE — the data must be fit-for-purpose and the methodology must meet scientific standards.